Holen Sie sich die Stockscreener-App
6.18
8.44%
-0.57
Handel nachbörslich:
6.17
-0.010
-0.16%
Artiva Biotherapeutics Inc Aktie (ARTV) Neueste Nachrichten
Artiva Biotherapeutics (NASDAQ:ARTV) Given Buy Rating at Needham & Company LLC - Defense World
Artiva Biotherapeutics, Inc. 2025 Annual Report: Business Overview, Risk Factors, and Strategic Outlook - Minichart
Artiva Biotherapeutics' (ARTV) Buy Rating Reiterated at Needham & Company LLC - MarketBeat
Artiva: Sufficient Cash Runway to 2027 Supports Buy Rating Ahead of Key 2026 RA Efficacy Readouts - TipRanks
ARTV: AlloNK shows promise in refractory RA as clinical and financial milestones approach in 2026 - TradingView
Artiva Biotherapeutics 10-K: Revenue $0.0M, Net Loss $(83.9)M — Cash $108.0M - TradingView
ARTV: 2025 net loss widened to $83.9M as R&D spending increased; cash runway extends into Q2 2027 - TradingView
Artiva Biotherapeutics posts 2025 results, prepares for RA clinical data in early 2026 - Traders Union
Artiva Biotherapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights - GlobeNewswire
Growth Value: Is Stantec Inc on track to beat earningsWeekly Volume Report & Expert Curated Trade Ideas - baoquankhu1.vn
What insider trading reveals about Artiva Biotherapeutics Inc. stock2026 Price Swings & Advanced Swing Trade Entry Plans - Naître et grandir
Dow Update: Does Artiva Biotherapeutics Inc have consistent dividend growthWeekly Gains Summary & Technical Buy Zone Confirmation - baoquankhu1.vn
Artiva Biotherapeutics Pivots to Rheumatoid Arthritis at TD Cowen, Teases 2026 RA Data Update - MarketBeat
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Artiva Biotherapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewswire
Artiva Biotherapeutics Appoints Thad Huston as Chief Financial Officer - The Globe and Mail
Artiva Biotherapeutics appoints Thad Huston as chief financial officer - Investing.com Australia
Artiva Biotherapeutics appoints Thad Huston as chief financial officer By Investing.com - Investing.com South Africa
Artiva Biotherapeutics, Inc. Appoints Thad Huston as Principal Financial Officer and Principal Accounting Officer, Effective from February 18, 2026 - marketscreener.com
Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant - The Globe and Mail
Artiva Biotherapeutics Announces Appointment Of Thad Huston As CFO - TradingView
Artiva Biotherapeutics Announces Appointment of Thad Huston - GlobeNewswire
Is Artiva Biotherapeutics Inc. on track to beat earningsJuly 2025 Retail & Daily Profit Maximizing Tips - mfd.ru
Artiva Biotherapeutics Inc. (ARTV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Can Artiva Biotherapeutics Inc. keep up with sector leaders2025 Institutional Moves & AI Driven Stock Movement Reports - mfd.ru
Will Artiva Biotherapeutics Inc. benefit from rate cutsJuly 2025 Weekly Recap & Consistent Profit Alerts - mfd.ru
Artiva Biotherapeutics appoints pharma veteran Elaine Sorg to board By Investing.com - Investing.com India
Earnings Miss: Does Artiva Biotherapeutics Inc. have consistent dividend growthWeekly Stock Report & Precise Trade Entry Recommendations - mfd.ru
Artiva Biotherapeutics Adds Veteran Executive Elaine Sorg to Board - The Globe and Mail
Artiva Biotherapeutics appoints pharma veteran Elaine Sorg to board - Investing.com Australia
Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors - Bitget
AtaiBeckley Appoints Michael Faerm as Chief Financial Officer - The Manila Times
Sell Signal: Is LINKBANCORP Inc a defensive stockJuly 2025 PreEarnings & High Yield Equity Trading Tips - baoquankhu1.vn
Aug Momentum: Does Artiva Biotherapeutics Inc have consistent dividend growth2025 Key Lessons & Precise Buy Zone Tips - baoquankhu1.vn
Will Artiva Biotherapeutics Inc. stock benefit from sector rotation2025 Dividend Review & Real-Time Buy Signal Notifications - mfd.ru
Can Artiva Biotherapeutics Inc. stock continue upward trendWeekly Loss Report & Free High Accuracy Swing Entry Alerts - mfd.ru
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Short Interest Down 28.5% in January - MarketBeat
Artiva Biotherapeutics, Inc. (RTVA.US) Latest News & Headlines - Longbridge
Is Artiva Biotherapeutics Inc. stock risky to hold nowJuly 2025 Momentum & Long-Term Growth Portfolio Plans - mfd.ru
Published on: 2026-02-12 04:11:50 - mfd.ru
Will Artiva Biotherapeutics Inc. outperform its industry peersPortfolio Update Report & Community Driven Trade Alerts - mfd.ru
Is Artiva Biotherapeutics Inc. stock a good pick for beginnersQuarterly Portfolio Review & AI Optimized Trading Strategy Guides - mfd.ru
Can Artiva Biotherapeutics Inc. stock outperform in a bear marketForecast Cut & Low Risk Investment Opportunities - mfd.ru
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $19.00 Average PT from Brokerages - Defense World
ARTV Stock Price and Chart — NASDAQ:ARTV - TradingView
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Artiva Biotherapeutics executes RSU exchange for employees - MSN
Trading Action: Is Artiva Biotherapeutics Inc stock a good pick for beginnersJuly 2025 Momentum & Community Consensus Trade Signals - baoquankhu1.vn
Hedge Fund Bets: Is CFRPRB stock heavily shortedTreasury Yields & Technical Pattern Recognition Alerts - baoquankhu1.vn
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Sees Significant Decline in Short Interest - MarketBeat
Pharma News: Can AGMH outperform under higher oil pricesTrade Exit Report & Technical Entry and Exit Tips - baoquankhu1.vn
Brokers Set Expectations for ARTV FY2030 Earnings - Defense World
Income Plays: Is Artiva Biotherapeutics Inc.’s ROE strong enoughJuly 2025 Opening Moves & Weekly Chart Analysis and Trade Guides - mfd.ru
Update Report: Can Artiva Biotherapeutics Inc. outperform in the next rallyJuly 2025 Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
Undervalued Penny Stocks To Consider In January 2026 - simplywall.st
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):